pdufa.bio
Home › Decisions › UNCY 2026-06-30

UNCY FDA decision — Jun 30, 2026

✕ COMPLETE RESPONSE LETTER

Unicycive Therapeutics Inc. — Oxylanthanum Carbonate (OLC) · Kidney disease.

Run-up into the decision (T-120 → T+5)

PDUFA 6/30/26$8.56$5.651/13/26
Daily close, T-120 (1/13/26) through T+5. Run-up high $8.56 on 5/18/26, low $5.65 on 1/13/26 (T-120 to T-1). FDA decision 6/30/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-06-30
OutcomeCRL
Drug / candidateOxylanthanum Carbonate (OLC)
CompanyUnicycive Therapeutics Inc.
120-day run-up (T-120→T-1)+36.3%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio